Should we use statins in treatment of polycystic ovary syndrome?

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 3, 2009, Pages 209-211

  Duleba, Antoni J ^a   Pawelczyk, Leszek ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; DOLICHOL; FARNESYL DIPHOSPHATE; FOLLITROPIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; SIMVASTATIN; SOMATOMEDIN C RECEPTOR; TESTOSTERONE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ANDROGEN SYNTHESIS; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR RISK; CELL HYPERPLASIA; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DYSLIPIDEMIA; EDITORIAL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PRENYLATION; RISK REDUCTION; STEROIDOGENESIS; TERATOGENICITY; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70049105110     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.1     Document Type: Editorial

References (21)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84(11), 4006-4011 (1999).
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89(6), 2745-2749 (2004).
3. Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin. Reprod. Med. 26(1), 39-44 (2008).
4. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91(1), 336-340 (2006).
5. Hughesdon PE. Morphology and morphogenesis of the Stein - Leventhal ovary and of so called "hyperthecosis". Obstet. Gynecol. Surv. 37, 59-77 (1982).
6. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol. 13(6), 946-957 (1999).
7. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab. 62(5), 904-910 (1986).
8. Duleba AJ, Spaczynski RZ, Arici A, Carbone R, Behrman HR. Proliferation and differentiation of rat theca-interstitial cells: comparison of effects induced by platelet-derived growth factor and insulin-like growth factor-I. Biol. Reprod. 60(3), 546-550 (1999).
9. Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertil. Steril. 69(2), 335-340 (1998).
10. Foyouzi N, Kwintkiewicz J, Duleba AJ. Modulation of steroidogenesis of theca-interstitial cells by oxidative stress and insulin. Presented at: 51st Annual Meeting of the Society for Gynecologic Investigation. Houston TX, USA, 24-27 March 2004.
11. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269 (1996).
12. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int. J. Cardiol. 90(2-3), 317-321 (2003).
13. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil. Steril. 82(Suppl. 3), 1193-1197 (2004).
14. Kwintkiewicz J, Foyouzi N, Piotrowski P, Rzepczynska I, Duleba AJ. Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase pathway. Fertil. Steril. 86(Suppl. 4), 1053-1058 (2006).
15. Dobs AS, Schrott H, Davidson MH et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metab. Clin. Exp. 49(9), 1234-1238 (2000).
16. Piotrowski P, Kwintkiewicz J, Rzepczynska I, Duleba AJ. Simvastatin and mevastatin inhibit expression of NADPH oxidase subunits: p22phox and p47phox in rat theca-interstitial cells. Presented at: 52nd Annual Meeting of the Society for Gynecologic Investigation. Los Angeles, CA, USA, 23-26 March 2005.
17. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil. Steril. 85(4), 996-1001 (2006).
18. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J. Clin. Endocrinol. Metab. 92(2), 456-461 (2007).
19. Kaya C, Cengiz SD, Berker B, Demirtas S, Cesur M, Erdogan G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil. Steril. (2008).
20. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab. 94(1), 103-108 (2009).
21. Taguchi N, Rubin ET, Hosokawa A et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod. Toxicol. 26(2), 175-177 (2008).